Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Moodys
McKesson
Colorcon
Medtronic

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR PEXIDARTINIB HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Pexidartinib Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01349036 ↗ A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma Terminated Plexxikon Phase 2 2011-12-03 The objective of this study is to evaluate the response of subjects with recurrent glioblastoma to continuous therapy of PLX3397.
NCT01349036 ↗ A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma Terminated Daiichi Sankyo, Inc. Phase 2 2011-12-03 The objective of this study is to evaluate the response of subjects with recurrent glioblastoma to continuous therapy of PLX3397.
NCT01525602 ↗ Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors Completed Plexxikon Phase 1 2012-05-01 This was a 3-part study designed to explore the safety and tolerability of escalating doses of PLX3397 with weekly paclitaxel to establish a recommended Phase 2 dose (RP2D), to confirm RP2D in participants with advanced non-resectable solid tumors, and to determine the efficacy of PLX3397 600 mg twice daily (BID) administered in combination with weekly paclitaxel in participants with advanced, metastatic or non-resectable, platinum-resistant or -refractory epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
NCT01525602 ↗ Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors Completed Daiichi Sankyo, Inc. Phase 1 2012-05-01 This was a 3-part study designed to explore the safety and tolerability of escalating doses of PLX3397 with weekly paclitaxel to establish a recommended Phase 2 dose (RP2D), to confirm RP2D in participants with advanced non-resectable solid tumors, and to determine the efficacy of PLX3397 600 mg twice daily (BID) administered in combination with weekly paclitaxel in participants with advanced, metastatic or non-resectable, platinum-resistant or -refractory epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
NCT01790503 ↗ A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed Plexxikon Phase 1/Phase 2 2013-07-18 The study objectives are to assess the potential for PLX3397 to improve the efficacy of standard of care radiation therapy (RT) + temozolomide in patients with newly diagnosed glioblastoma (GBM).
NCT01790503 ↗ A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed Daiichi Sankyo, Inc. Phase 1/Phase 2 2013-07-18 The study objectives are to assess the potential for PLX3397 to improve the efficacy of standard of care radiation therapy (RT) + temozolomide in patients with newly diagnosed glioblastoma (GBM).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pexidartinib Hydrochloride

Condition Name

Condition Name for Pexidartinib Hydrochloride
Intervention Trials
Tenosynovial Giant Cell Tumor 4
Melanoma 2
Gastrointestinal Stromal Tumor (GIST) 2
Pharmacokinetics in Healthy Volunteers 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pexidartinib Hydrochloride
Intervention Trials
Giant Cell Tumors 4
Giant Cell Tumor of Tendon Sheath 4
Neoplasms 3
Gastrointestinal Stromal Tumors 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pexidartinib Hydrochloride

Trials by Country

Trials by Country for Pexidartinib Hydrochloride
Location Trials
United States 68
Korea, Republic of 6
Australia 5
Taiwan 4
Italy 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pexidartinib Hydrochloride
Location Trials
New York 8
California 7
Massachusetts 7
Texas 6
Michigan 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pexidartinib Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Pexidartinib Hydrochloride
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 2 2
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pexidartinib Hydrochloride
Clinical Trial Phase Trials
Completed 11
Active, not recruiting 2
Recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pexidartinib Hydrochloride

Sponsor Name

Sponsor Name for Pexidartinib Hydrochloride
Sponsor Trials
Plexxikon 13
Daiichi Sankyo, Inc. 11
Daiichi Sankyo Co., Ltd. 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pexidartinib Hydrochloride
Sponsor Trials
Industry 35
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Johnson and Johnson
McKinsey
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.